Perspectives in weight control in diabetes – Survodutide

Jun 17, 2023Diabetes research and clinical practice

Views on Weight Control in Diabetes Using Survodutide

AI simplified

GLP-1 TherapiesGLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Survodutide, a novel dual GCGR/GLP-1R agonist, has shown glucose-lowering efficacy and clinically meaningful body weight loss in a Phase II trial.

  • Survodutide is a 29-amino acid peptide derived from glucagon, designed to mimic the natural gut hormone oxyntomodulin.
  • The incorporation of a C18 diacid allows for binding to albumin, which prolongs the drug's half-life for once-weekly dosing.
  • GCGR agonism in survodutide may enhance body weight loss by increasing energy expenditure alongside the appetite-reducing effects of GLP-1R agonists.
  • The treatment has been demonstrated to effectively reduce glycated hemoglobin levels in patients with Type 2 diabetes mellitus and obesity.
  • Dual GCGR/GLP-1R agonism could provide greater therapeutic benefits compared to GLP-1R agonism alone.

AI simplified

Full Text

Full text is available at the source.
View full text (XML) ↗View full text ↗

Related papers

Apr '24
Biomarkers and drug effects of survodutide, a medicine targeting two hormone receptors, for choosing clinical use
top 5% journal
cited by 12 papers
research support, non-u.s. gov't
Nov '22
BI 456906: Discovery and early testing of a new drug that targets two hormone receptors to strongly reduce obesity
top 5% journal
cited by 114 papers
research support, non-u.s. gov't
May '21
Partial activation improves blood sugar control by a hormone-based treatment targeting two related receptors
top 5% journal
cited by 15 papers
research support, non-u.s. gov't
Jul '09
Activating both GLP-1 and glucagon receptors reverses obesity in mice
top 5% journal
cited by 367 papers
journal article
Jan '23
New developments in peptide treatments for type 2 diabetes and obesity
cited by 86 papers
journal article
Jul '21
Long-Lasting Modified Frog GLP-1 Compounds That Activate Both GLP-1 and Glucagon Receptors to Treat Metabolic Disease
top 20% journal
cited by 9 papers
research support, non-u.s. gov't
Jul '18
Combined Effects of Glucagon and GLP-1 Drugs in Obese Diabetic Monkeys
top 10% journal
cited by 22 papers
research support, non-u.s. gov't
Jun '24
Using glucagon to treat metabolic diseases like type 2 diabetes and obesity
top 5% journal
cited by 30 papers
journal article
May '16
Treating diabetes and obesity by activating two hormone receptors called 'twincretins'
cited by 53 papers
journal article

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #30
Tirzepatide beats semaglutide for heart protection in 70,672 non-diabetic adults with obesity
4 days ago7 studies
issue #29
Stopping GLP-1 drugs before endoscopy cuts stomach content risk from 25% to 3%
1 week ago7 studies
issue #28
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
2 weeks ago3 studies
issue #27
GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans
3 weeks ago7 studies
issue #26
86.5% of patients on semaglutide or tirzepatide lost at least 5% of body weight at 6 months in Medicaid study
4 weeks ago7 studies
issue #25
GLP-1 drugs linked to 20% lower dementia risk in diabetic kidney patients
5 weeks ago7 studies
issue #24
Tirzepatide beats semaglutide for weight loss by 6.1% in head-to-head comparison
6 weeks ago7 studies
issue #23
Bariatric Surgery vs. GLP-1s for cardiovascular risk
7 weeks ago7 studies
issue #22
GLP-1 drugs linked to better pregnancy rates in PCOS women and reduced cancer risk in diabetes patients
8 weeks ago7 studies
issue #21
GLP-1 drugs may fight addiction, and reduce alcohol consumption
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief